Stay up to date on recent advances in the multidisciplinary approach to cancer.
Zanidatamab Recommended For Conditional Marketing Approval in Advanced HER2+ BTC
The recommendation from the CHMP is based on results from the phase 2b HERIZON-BTC-01 trial of zanidatamab in advanced HER2+ biliary tract cancer.
Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors
A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.
Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma
The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.
Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
Same-Day G-CSF After Chemo Appears Safe, Efficacious in Breast Cancer
No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.
Frailty Assessments Indicate Severe AE Probability in Prostate Cancer
BMI, serum albumin, and G8 screening tool scores were all factors correlated with the likelihood of experiencing a grade 3 or higher AE.
